This Plain Language Summary of Publication article (PLSP) from Future Oncology compares datopotamab deruxtecan (an antibody-drug conjugate) to docetaxel chemotherapy in 604 patients with advanced non-small cell lung cancer whose previous treatments had failed. Participants were randomly assigned to receive either treatment, and researchers measured overall survival and progression-free survival to determine which drug was more effective for patients with treatment-resistant advanced lung cancer.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study’ and was published in the Journal of Clinical Oncology.

Visit ASCO using the link to read the original article.